-
公开(公告)号：EP2603210A1
公开(公告)日：2013-06-19
申请号：EP11748700.9
申请日：2011-08-12
申请人： UCL Business Plc.
IPC分类号： A61K31/00 , A61K31/417 , A61K31/4178 , A61K31/475 , A61P1/16
CPC分类号： A61K31/4375 , A61K31/00 , A61K31/417 , A61K31/4178 , A61K31/475 , G01N33/6893
摘要： The present invention derives from the finding that increased levels of alpha 2a adrenergic receptors (ADRA2a) are associated with chronic liver disease and that by decreasing ADRA2a levels
in vivo, a number of symptoms and consequences of chronic liver disease may be reduced. Accordingly, the invention provides ADRA2a antagonists for use in a method of treating an individual suffering from liver disease.-
12.发明公开
公开(公告)号：EP1824563A1
公开(公告)日：2007-08-29
申请号：EP05808837.8
申请日：2005-11-28
申请人： UCL Business PLC
发明人： JALAN, Rajiv , JALAN, Kamal, Nayan
IPC分类号： A61P1/16 , A61K31/192 , A61K31/198
CPC分类号： A61K31/198 , A61K31/192 , A61K2300/00
摘要： The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.
-
13.发明公开
公开(公告)号：EP2988825A1
公开(公告)日：2016-03-02
申请号：EP14719826.1
申请日：2014-04-23
申请人： UCL Business Plc.
IPC分类号： A61P13/12 , G01N33/48 , A61K31/7076 , A61K38/16
CPC分类号： A61K38/1709 , A61K31/7076 , G01N33/502 , G01N33/5044 , G01N33/5088 , G01N2333/705 , G01N2800/347
摘要： The present invention relates to the treatment or prevention of kidney injury and in particular acute kidney injury, such as acute kidney injury associated with cirrhosis. The invention relates to the treatment or prevention of such injury by administration of an agonist of the P2X7 receptor.
-
公开(公告)号：EP2475370A1
公开(公告)日：2012-07-18
申请号：EP10755211.9
申请日：2010-09-09
申请人： UCL Business PLC
IPC分类号： A61K31/575 , A61K39/395 , A61P1/16
CPC分类号： C07K16/241 , A61K31/00 , A61K31/575 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention derives from the finding that decreased levels of DDAH I are associated with increased portal pressure and that by increasing DDAH I levels in vivo, portal pressure may be reduced. Accordingly, the invention provides methods for reducing portal blood pressure comprising administering to a subject in need thereof an agonist of DDAH I.
-
公开(公告)号：EP2059817B1
公开(公告)日：2010-11-17
申请号：EP07804163.9
申请日：2007-09-07
申请人： UCL Business PLC
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/765 , G01N2800/085
摘要： A method for assessing liver function in an individual, which method comprises determining the level of methylarginine(s) (such as ADMA and/or SDMA) and the ratio of ischemia modified albumin (IMA): albumin ratio (IMAR) in the individual', thereby to assess liver function in the individual.
-
公开(公告)号：EP2061533A2
公开(公告)日：2009-05-27
申请号：EP07824370.6
申请日：2007-10-29
申请人： UCL Business PLC
发明人： DAVIES, Nathan , JALAN, Rajiv
IPC分类号： A61M1/34
CPC分类号： A61M1/3496
摘要： The invention provides an apparatus for use in the treatment of an individual suffering from liver disease, including: (a) means for selectively removing albumin from the blood of the individual; and (b) means for selectively removing endotoxin from the blood of the individual.
-
公开(公告)号：EP2059817A1
公开(公告)日：2009-05-20
申请号：EP07804163.9
申请日：2007-09-07
申请人： UCL Business PLC
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/765 , G01N2800/085
摘要： A method for assessing liver function in an individual, which method comprises determining the level of methylarginine(s) (such as ADMA and/or SDMA) and the ratio of ischemia modified albumin (IMA): albumin ratio (IMAR) in the individual', thereby to assess liver function in the individual.
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.021 秒)
